- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07940283
Effects of a Combination of Bifidobacterium Longum Subsp. Longum Strains on Stress and Related Health Outcomes in Young Adult
Effect of Bifidobacterium Longum Subsp. Longum Combination Intervention on Stress Status and Related Health Outcomes: A Randomized, Double-Blind, Placebo-Controlled Clinical Study
This study is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the effects of a combination of Bifidobacterium longum subsp. longum strains on stress-related health outcomes in adults. The study plans to enroll 126 adults experiencing stress-related problems, who will be randomly assigned in equal proportions to either the probiotic group or the placebo group and will receive the assigned intervention for 8 weeks. Participants will complete the scheduled study visits and assessments.
The study will systematically evaluate the principal health concerns of young adults experiencing high levels of stress through multiple approaches, including subjective questionnaire assessments, biological sample testing, and gut microbiome analysis. The main assessments will include a comparison of changes in stress status before and after the intervention between the probiotic and placebo groups using validated psychological assessment instruments. The effects of the intervention on sleep quality, quality of life, and related emotional states will also be evaluated. Sleep quality and quality of life will be assessed using validated assessment instruments.
To further investigate the potential biological mechanisms, stool samples will be collected from participants for gut microbiome metagenomic analysis to characterize changes in microbial composition and functional features. Laboratory-based assays will also be used to measure stress-, immune-, and inflammation-related biomarkers. This study is expected to provide preliminary evidence supporting the clinical application of microbiota-targeted interventions based on modulation of the gut-brain axis in populations experiencing high levels of stress.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Yuan Jie
- Telefoonnummer: +86 198 2187 2781
- E-mail: peanut.yuan@diprobio.com
Studie Locaties
-
-
Gansu
-
Lanzhou, Gansu, China, 730030
- Northwest Minzu University
-
Contact:
- Jie Yuan
- Telefoonnummer: +86 13308178331
- E-mail: 13308178331@163.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults aged 18-65 years.
- Perceived Stress Scale-10 (PSS-10) score ≥ 14.
- Voluntary participation in the study and provision of written informed consent before any study procedures begin.
Exclusion Criteria:
- Use of probiotic supplements or probiotic-containing products within 4 weeks before enrollment.
- Use of antibiotics or systemic glucocorticoids within 4 weeks before enrollment.
- Current or previous diagnosis of psychiatric disorders (e.g., schizophrenia or major depressive disorder), epilepsy, major endocrine disorders, active inflammatory bowel disease or other severe gastrointestinal disorders, or severe sleep disturbances requiring treatment adjustment.
- Use of medications or dietary supplements that may affect the gut-brain axis, sleep, mood, or stress status assessment within 4 weeks before enrollment, including but not limited to sedative-hypnotics, anxiolytics, antidepressants, antipsychotics, mood stabilizers, and supplements with sleep-inducing, sedative, or stress-relieving effects (e.g., magnesium-containing supplements).
- Pregnant or breastfeeding women.
- Known allergy to the study product or any of its components.
- Smoking or alcohol consumption on the day of the study visit or within 48 hours before the visit.
- Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 3 months.
- Insufficient compliance, as judged by the investigator, to complete sample collection or study-related documentation as required by the study protocol.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Probiotic group
Participants receive Bifidobacterium longum subspecies combination formulation. |
Participants receive an oral probiotic combination formulation according to the study protocol for the duration of the intervention. |
|
Placebo-vergelijker: Placebo group
Participants receive a matching placebo formulation. |
Participants receive a matching placebo formulation according to the same administration schedule as the probiotic intervention. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Depression Anxiety Stress Scales-42 (DASS-42) Stress Subscale Score
Tijdsspanne: Baseline, Week 4, Week 8
|
Stress levels will be assessed using the Stress subscale of the 42-item Depression Anxiety Stress Scales (DASS-42). The subscale consists of 14 items, each scored from 0 to 3. The total Stress subscale score ranges from 0 to 42, with higher scores indicating greater stress severity. Raw scores will be reported at each assessment time point. |
Baseline, Week 4, Week 8
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pittsburgh Sleep Quality Index (PSQI) Global Score
Tijdsspanne: Baseline, Week 4, Week 8
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The global score is calculated by summing seven component scores, each ranging from 0 to 3. The total global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Raw PSQI global scores will be reported at each assessment time point. |
Baseline, Week 4, Week 8
|
|
WHOQOL-BREF Physical Health Domain Score
Tijdsspanne: Baseline, Week 4, Week 8
|
Quality of life in the physical health domain will be assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire. Domain scores will be transformed to a scale ranging from 0 to 100, with higher scores indicating better quality of life in the corresponding domain. Raw transformed domain scores will be reported at each assessment time point. |
Baseline, Week 4, Week 8
|
|
Relative Abundance of Prespecified Gut Microbial Taxa
Tijdsspanne: Baseline, Week 4, Week 8
|
The relative abundance of prespecified gut microbial taxa will be assessed using shotgun metagenomic sequencing of fecal samples. Relative abundance will be expressed as a percentage of the total taxonomic abundance assigned to the selected taxa at each assessment time point. |
Baseline, Week 4, Week 8
|
|
Gut stress and immune biomarkers
Tijdsspanne: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- XBMU-YX-20260038
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .